NCT02415023View on ClinicalTrials.gov

A Phase Ib/2 Clinical Study of Fruquintinib Combined With Paclitaxel in the Treatment of Advanced Gastric Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

November 9, 2014

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions
Gastric Cancer
Interventions
DRUG

fruquintinib+paclitaxel

28-day cycle of fruquintinib qd for 3 weeks followed by 1-week break combined with paclitaxel 80 mg/m2

Trial Locations (3)

100142

Hutchison Medi Pharma Investigational Site, Beijing

200032

Hutchison Medi Pharma Investigational Site, Shanghai

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Hutchison Medipharma Limited

INDUSTRY

NCT02415023 - A Phase Ib/2 Clinical Study of Fruquintinib Combined With Paclitaxel in the Treatment of Advanced Gastric Cancer | Biotech Hunter | Biotech Hunter